TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07250646: A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Sponsor: Aspera Biomedicines, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 28 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07250646 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07250646 Rescue Dossier →